<DOC>
	<DOCNO>NCT00440986</DOCNO>
	<brief_summary>The purpose study determine best durable choice treatment phlebotomy eritrocytoapheresis medium- long-term clinical management HH</brief_summary>
	<brief_title>Clinical Management Hereditary Hemochromatosis : Phlebotomy vs. Erythrocytoapheresis</brief_title>
	<detailed_description>Patients affect Hereditary hemochromatosis need completeinitial stag disease , correct clinical management , good chance treatment long-term follow-up . Clinical manifestation presentation follow-up may consistently vary accord diagnostic criterion , treatment option follow-up durability , interruption . So , 25 caucasian patient , 16 male 6 female age &gt; 18 yr . consecutively diagnose randomly include two arm treatment , phlebotomy vs. eritrocytoapheresis , evaluate , baseline 6-12-18-24-36 month , clinical status concern liver , kidney , pancreas , heart , endocrine iron overload function final outcome relate therapeutic strategy , include cost/effectiveness analysis</detailed_description>
	<mesh_term>Hemochromatosis</mesh_term>
	<criteria>Patiens newly diagnose Hereditary Hemochromatosis Age &lt; 18 yr . Not obese ( BMI &lt; 30 ) Not consume alchol beverage , Not affected systemic disease know hepatic virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Clinical Management</keyword>
	<keyword>Phlebotomy</keyword>
	<keyword>Eritrocytoapheresis</keyword>
</DOC>